Le Lézard
Classified in: Health
Subject: ATY

IRHYTHM SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against iRhythm Technologies, Inc. - IRTC


NEW ORLEANS, Feb. 9, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 8, 2024 to file lead plaintiff applications in a securities class action lawsuit against iRhythm Technologies, Inc. (NasdaqGS: IRTC), if they purchased the Company's shares between January 11, 2022, and May 30, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.

Get Help

iRhythm investors should visit us at https://claimsfiler.com/cases/nasdaq-irtc-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

iRhythm and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On May 30, 2023, the Company disclosed the receipt of a Warning Letter from the FDA regarding "non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Company's Zio AT System and medical device quality system requirements," specifically addressing a series of deficiencies tied to the marketing and capabilities of the Zio AT device that potentially posed a known but undisclosed risk to patients, for example transmission limits of arrhythmia or heart irregularity events.

On this news, the price of iRhythm's shares fell $7.41 per share, or 6.1%, from a closing price of $121.68 on May 30, 2023, to a closing price of $114.27 on May 31, 2023.

The case is Glazing Employers and Glaziers' Union Local #27 Pension and Retirement Fund v. iRhythm Technologies, Inc., No. 24-cv-706.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler


These press releases may also interest you

at 21:03
As the demand for surgical precision and faster patient recovery continues to grow, smart healthcare has achieved another major breakthrough. Since 2006, Chang Gung Memorial Hospital has pioneered the use of the Da Vinci Robotic Surgical Systems. By...

at 20:30
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been...

at 20:15
CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab....

at 20:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:56
Clover Biopharmaceuticals, Ltd.?(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced IND clearance by U.S....

at 19:30
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug...



News published on and distributed by: